-$0.19 EPS Expected for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) This Quarter

Wall Street analysts predict that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will announce ($0.19) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Lexicon Pharmaceuticals’ earnings, with estimates ranging from ($0.23) to ($0.17). Lexicon Pharmaceuticals posted earnings of ($0.26) per share during the same quarter last year, which would suggest a positive year over year growth rate of 26.9%. The company is expected to announce its next earnings report on Thursday, November 7th.

According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full year earnings of ($0.80) per share for the current fiscal year, with EPS estimates ranging from ($0.89) to ($0.75). For the next financial year, analysts anticipate that the business will post earnings of ($0.66) per share, with EPS estimates ranging from ($1.23) to $0.07. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.13). The company had revenue of $9.68 million for the quarter, compared to analysts’ expectations of $28.52 million. During the same quarter last year, the firm earned ($0.33) EPS. The business’s revenue for the quarter was down 29.9% compared to the same quarter last year.

Several research firms recently commented on LXRX. Wedbush restated an “outperform” rating and issued a $17.00 price target (down previously from $35.00) on shares of Lexicon Pharmaceuticals in a report on Thursday, August 1st. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 19th. Citigroup cut their price target on shares of Lexicon Pharmaceuticals from $15.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, July 30th. Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 3rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the stock. Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $7.63.

In other news, Director Sam L. Barker acquired 24,000 shares of the stock in a transaction on Friday, August 2nd. The stock was bought at an average price of $1.18 per share, with a total value of $28,320.00. Following the completion of the transaction, the director now directly owns 40,187 shares of the company’s stock, valued at $47,420.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.40% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of LXRX. First Manhattan Co. acquired a new stake in Lexicon Pharmaceuticals in the first quarter valued at approximately $15,282,000. Pictet Asset Management Ltd. grew its position in Lexicon Pharmaceuticals by 42.6% in the first quarter. Pictet Asset Management Ltd. now owns 586,850 shares of the biopharmaceutical company’s stock valued at $3,263,000 after acquiring an additional 175,400 shares in the last quarter. Norges Bank acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $1,005,000. Fosun International Ltd grew its position in shares of Lexicon Pharmaceuticals by 79.9% during the first quarter. Fosun International Ltd now owns 181,000 shares of the biopharmaceutical company’s stock worth $952,000 after buying an additional 80,379 shares in the last quarter. Finally, Birchview Capital LP grew its position in shares of Lexicon Pharmaceuticals by 300.0% during the first quarter. Birchview Capital LP now owns 80,000 shares of the biopharmaceutical company’s stock worth $445,000 after buying an additional 60,000 shares in the last quarter. 98.28% of the stock is owned by institutional investors.

NASDAQ LXRX traded down $0.06 during mid-day trading on Monday, hitting $1.47. The company’s stock had a trading volume of 1,451,700 shares, compared to its average volume of 974,037. Lexicon Pharmaceuticals has a 52-week low of $1.13 and a 52-week high of $11.88. The company has a fifty day moving average price of $4.56. The stock has a market cap of $136.03 million, a price-to-earnings ratio of -1.29 and a beta of 0.77.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Story: Buy Rating

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.